Trinity Biotech (TRIB) Net Margin (2009 - 2024)
Trinity Biotech (TRIB) posted quarterly Net Margin of 106.92% for Q4 2024, down 6595.0% year-on-year from 1.65% in Q1 2024, and down 240.43% on a QoQ basis from 31.41% in Q3 2024.
Trinity Biotech (TRIB) Net Margin (2009 - 2024) Analysis & Trends
Trinity Biotech (TRIB) has reported Net Margin for 16 consecutive years, with 106.92% the latest figure, recorded in Q4 2024.
- Quarterly Net Margin fell 6595.0% year-over-year to 106.92% in Q4 2024, while the trailing twelve-month figure through Dec 2024 was 51.64% (down 938.0% YoY) and the FY2025 annual result came in at 85.42%, down 3376.0% from the prior year.
- Net Margin eased to 106.92% in Q4 2024 per TRIB's latest filing, from 31.41% in the prior quarter.
- Over the last five years, Net Margin for TRIB reached as high as 22.88% in Q3 2020 and fell as low as 106.92% in Q4 2024.
- A 5-year average of 32.98% and a median of 35.29% in 2023 frame the typical range for Net Margin.
- Annual changes were most pronounced in 2022 — Net Margin plunged 8459 bps — and 2023, when it jumped 3916 bps.
- Year by year, Net Margin stood at 30.59% in 2020, then soared by 79 bps to 6.47% in 2021, then sank by 890 bps to 64.1% in 2022, then surged by 36 bps to 40.97% in 2023, then plunged by 161 bps to 106.92% in 2024.
- According to Business Quant data, Net Margin over the past three periods registered 106.92%, 31.41%, and 42.65% for Q4 2024, Q3 2024, and Q2 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 9.65% |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 12.38% |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 12.84% |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 25.77% |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | - |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 16.74% |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 3.87% |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 8.01% |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Trinity Biotech | 93,750.00 | -5.04 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -106.92% |
| Sep 30, 2024 | -31.41% |
| Jun 30, 2024 | -42.65% |
| Mar 31, 2024 | -22.56% |
| Dec 31, 2023 | -40.97% |
| Sep 30, 2023 | -45.79% |
| Jun 30, 2023 | -43.09% |
| Mar 31, 2023 | -39.17% |
| Dec 31, 2022 | -64.10% |
| Sep 30, 2022 | -56.96% |
| Jun 30, 2022 | -62.96% |
| Mar 31, 2022 | -78.33% |
| Dec 31, 2021 | -6.47% |
| Sep 30, 2021 | 6.00% |
| Jun 30, 2021 | -3.03% |
| Mar 31, 2021 | 6.26% |
| Dec 31, 2020 | -30.59% |
| Sep 30, 2020 | 22.88% |
| Jun 30, 2020 | -9.16% |
| Mar 31, 2020 | -10.49% |